Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Akebia Therapeutics to post earnings of ($0.09) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $56.20 million during the quarter, compared to analyst estimates of $55.64 million. During the same period in the previous year, the company posted ($0.04) earnings per share. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Trading Down 6.0 %

Shares of NASDAQ AKBA opened at $1.40 on Wednesday. Akebia Therapeutics has a twelve month low of $0.78 and a twelve month high of $2.48. The company has a market capitalization of $293.12 million, a price-to-earnings ratio of -5.00 and a beta of 0.94. The firm has a 50-day moving average of $1.56 and a two-hundred day moving average of $1.36.

Analyst Ratings Changes

AKBA has been the subject of a number of research analyst reports. StockNews.com downgraded shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, April 29th. HC Wainwright upped their price target on shares of Akebia Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, March 28th.

Insiders Place Their Bets

In other Akebia Therapeutics news, CEO John P. Butler sold 46,570 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $1.58, for a total transaction of $73,580.60. Following the sale, the chief executive officer now owns 2,044,580 shares in the company, valued at approximately $3,230,436.40. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO John P. Butler sold 46,570 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $1.58, for a total value of $73,580.60. Following the transaction, the chief executive officer now owns 2,044,580 shares in the company, valued at approximately $3,230,436.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John P. Butler sold 37,733 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $1.52, for a total value of $57,354.16. Following the completion of the transaction, the chief executive officer now owns 2,091,150 shares in the company, valued at approximately $3,178,548. The disclosure for this sale can be found here. In the last quarter, insiders have sold 117,093 shares of company stock worth $181,654. Company insiders own 3.84% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.